olaparib
astrazeneca,merck
['propel', 'olaparib', 'brca', '1357o']
#esmo22 abs# 1357o: updated results from the propel trial showed rpfs benefit of using aap + olaparib for all subgroups (non-hrrm, hrrm,brcam status). improved os with aap + olaparib vs aap +placebo is reported (hr 0.83). 
DM Clinical Hematology/BMT (PGI, Chandigarh), Hematology/Oncology Fellow at Huntsman Cancer Institute, SLC, Utah, United States ( GU Oncologist in making !!??)